35 research outputs found
Demographic and clinical characteristics of the sample across BMI tertiles.
<p>Data are percentages and means ± standard deviations. HADS = Hospital anxiety and depression scale.</p
Logistic regression of presence of problems in mobility, self care and usual activities (EQ5D) and presence of anxiety and depression (HADS) by BMI tertiles and by continuous BMI.
<p>Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L; Presence of anxiety and depression defined as HADS anxiety subscale score ≥8.</p><p>* P<0.05.</p><p>**P<0.001.</p><p>Model 1 adjusting for age and sex.</p><p>Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.</p
Linear regression of BMI predicting IWQOL-Lite subscale and total scores and perceived health status (EQ5D-3L VAS) in whole sample and stratified by gender.
<p>U.B.  = Unstandardized Beta, S.E.  = Standard error, S.B  = Standardised Beta.</p><p>*P<0.05, **P<0.001.</p><p>Model 1 adjusting for age, gender and interaction between BMI and gender.</p>†<p>Model 1 and 2 adjusting for age only.</p><p>Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.</p
Risk of bias summary.
<p>Review authors’ judgements about each risk of bias item for each included study.</p
Participant characteristics.
<p>Characteristics of the eighteen studies included in the qualitative synthesis: Population, eligibility criteria, baseline lipid levels, use of antiretroviral and lipid lowering drugs.</p><p>NR  =  not recorded.</p><p>LLM  =  lipid modification medication.</p><p>ART  =  antiretroviral therapy.</p><p>PIs  =  protease inhibitors.</p><p>RTV  =  ritonavir.</p><p>BMI  =  body mass index.</p><p>DM  =  diabetic.</p><p>CVD  =  cardiovascular disease.</p><p>HOMA-IR  =  insulin resistance.</p><p>Conversion factor used: x 0.01129 for mg/dl to mmol/l.</p
Forest plot for effect of omega-3 supplementation on cholesterol levels (mmol/l).
<p>Studies are ranked from low to high baseline cholesterol levels. Illustrates subgroup analysis of concurrent use of lipid lowering medication (LLM) on treatment effects of omega-3 supplementation on Cholesterol levels.</p
Study characteristics.
<p>Characteristics of the eighteen studies included in the qualitative synthesis: setting, sample size, intervention, control, and duration.</p>*<p>median value.</p>§<p>unpublished data.</p><p>¶ estimated, not reported by study.</p><p>n  =  number of participants analysed.</p><p>N  =  number randomised.</p><p>bd  =  twice daily.</p><p>tds  =  three times a day.</p><p>EPA  =  eicosapentaenoic acid.</p><p>DHA  =  docosahexaenoic acid.</p><p>NCEP  =  National Cholesterol Education Programme <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038121#pone.0038121-National1" target="_blank">[26]</a>.</p><p>wk  =  week.</p><p>Ax  =  assessment.</p><p>DEXA  =  dual-energy x-ray absorptiometry.</p
Forest plot for effect of various dietary interventions on triglyceride levels (mmol/l).
<p>Studies are ranked from low to high baseline triglyceride levels. Illustrates weighted mean difference in triglyceride levels between dietary intervention or omega-3 supplementation and control group.</p
Prisma flow diagram of study selection and exclusion.
<p>Prisma flow diagram of study selection and exclusion.</p
Adjusted odds ratios for combined risk factors and mortality<sup>a</sup>.
a<p>Adjusting for sex, age (5 yrs group), education (no/primary, secondary, tertiary or higher), place of birth, housing (public housing, hut/shared, self owned, quarter/others) and job (sedentary, light, moderate, heavy, none).</p><p>*P<0.05, **P<0.01, ***P<0.001.</p